Anastasios Lymperopoulos

Anastasios Lymperopoulos, Ph.D., FAHA, FESC, is an Associate Professor in the Department of Pharmaceutical Sciences at Nova Southeastern University's Barry and Judy Silverman College of Pharmacy. He holds a Ph.D. in Pharmacology and M.Sc. in Medicinal Chemistry from the University of Patras, Greece. His research laboratory focuses on neurohormonal regulation in cardiovascular disease, specializing in G protein-coupled receptor (GPCR) pharmacology, adrenal-catecholamine signaling, and molecular mechanisms of heart failure.

Research Interests: Dr. Lymperopoulos investigates GPCR kinase (GRK) and beta-arrestin pathways in adrenal aldosterone/catecholamine production, biased agonism at angiotensin receptors, RGS protein functions, and therapeutic targeting of epicardial fat in atrial fibrillation. Collaborative projects span universities in Italy (Federico II), Temple, Florida, and Miami.

Recent Publications (2023-2025): Focus on cardiac GPCR signaling (GLP-1R, FFAR3), adrenal-kidney crosstalk in heart failure, SGLT2 inhibitor mechanisms (dapagliflozin), and metabolomics of epicardial fat. Trends highlight inflammation modulation, receptor crosstalk, and translational pharmacology.

Awards & Honors:

• Fellow, American Heart Association (FAHA) and European Society of Cardiology (FESC)
• Scientist Development Grant, AHA (09SDG2010138)
• Finalist: Melvin L. Marcus Young Investigator Award & ESC Cardiovascular Research Award

Grants & Patents:

• NIH R01 #HL155718-01 (Co-PI): Epicardial adipose tissue in atrial fibrillation
• U.S. Patent 10,172,907: Therapeutic modulation of aldosterone in heart disease
• Provisional patents: Adrenal GRK2 targeting and heart failure therapeutics

Advising & Lab: Mentors PhD/PharmD students in cardiovascular research. Lab team studies adrenal GPCRs, GRK/β-arrestin pathways, and neurohormonal control via in vitro/vivo models.